The aim of the study is to investigate whether women on oral contraceptives (OCs) suffering
from acquired OC-associated female sexual dysfunction (FSD) for at least 3 months but no
longer than one year will express the same level of sexual distress when taking SH T00658ID
compared to Microgynon, the usual OC prescribed for women with OC-associated FSD.
Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache
The aim of the present study is to investigate whether women taking a new combined oral
contraceptive pill (SH T00658ID, estradiol valerate/dienogest) experience fewer hormone
withdrawal-associated symptoms such as pelvic pain or headache during their monthly cycle
compared to a commonly used contraceptive pill (Microgynon).
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.